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Abstract
Background: Despite the recent publication of results from two randomized clinical trials, prostate specific antigen
(PSA) screening for prostate cancer remains a controversial issue. There is lack of agreement across studies that PSA
screening significantly reduces prostate cancer mortality. In spite of these facts, the widespread use of PSA testing
in the United States leads to overdetection and overtreatment of clinically indolent prostate cancer, and its
associated harms of incontinence and impotence.
Discussion: Given the inconclusive results from clinical trials and incongruent PSA screening guidelines, the
decision to screen for prostate cancer with PSA testing is an uncertain one for patients and health care providers.
Screening guidelines from some health organizations recommend an informed decision making (IDM) or shared
decision making (SDM) approach for deciding on PSA screening. These approaches aim to empower patients to
choose among the available options by making them active participants in the decision making process. By
increasing involvement of patients in the clinical decision-making process, IDM/SDM places more of the
responsibility for a complex decision on the patient. Research suggests, however, that patients are not well-
informed of the harms and benefits associated with prostate cancer screening and are also subject to an
assortment of biases, emotion, fears, and irrational thought that interferes with making an informed decision. In
response, the IDM/SDM approaches can be augmented with strategies from the philosophy of libertarian
paternalism (LP) to improve decision making. LP uses the insights of behavioural economics to help people better
make better choices. Some of the main strategies of LP applicable to PSA decision making are a default decision
rule, framing of decision aids, and timing of the decision. In this paper, we propose that applying strategies from
libertarian paternalism can help with PSA screening decision-making.
Summary: Our proposal to augment IDM and SDM approaches with libertarian paternalism strategies is intended
to guide patients toward a better decision about testing while maintaining personal freedom of choice. While PSA
screening remains controversial and evidence conflicting, a libertarian-paternalism influenced approach to decision
making can help prevent the overdiagnosis and overtreatment of prostate cancer.
Background
Screening for prostate cancer using prostate specific anti-
gen (PSA) has become widespread despite the controversy
surrounding the practice. For men, prostate cancer is the
most commonly diagnosed cancer in the US and the sec-
ond leading cause of cancer death. In 2010, approximately
217,730 men were diagnosed with prostate cancer and
32,050 men died, illustrating the public health burden of
this disease and the need for the identification of effective
methods to reduce prostate cancer mortality [1].
Unfortunately, there is a lack of conclusive evidence of
the value of PSA screening in the reduction of mortality;
two randomized controlled PSA screening trials, one in
Europe and the other in the US, recently reported dispa-
rate results for the effect of PSA testing on prostate can-
cer mortality [2,3]. The European study reported a 20%
relative reduction in prostate cancer mortality with
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any medium, provided the original work is properly cited.screening while the American trial reported no mortality
difference. The hope that these studies would provide
further clarity and direction for PSA screening did not
materialize. A more recently published population-based
screening trial reported a cumulative relative risk reduc-
tion of death as a result of prostate cancer of 50% in the
screening group, however the risk of overdiagnosis was
still substantial [4]. In addition to the inconsistent results
of the clinical trials, there is disagreement in PSA screen-
ing guidelines from major health organizations [5-8].
The fact that PSA testing leads to overdiagnosis and
overtreatment of prostate cancer and subsequent harms,
such as incontinence and impotence, adds to the contro-
versy about PSA screening. Given the ongoing contro-
versy, the responsibility for the decision to screen a man
for prostate cancer is a key issue in the PSA debate. In
this paper, we discuss the challenges of decision making
for PSA screening for prostate cancer and argue for aug-
menting the existing approaches of informed decision
making (IDM) and shared decision making (SDM) with




Traditionally, medical practice has been a paternalistic sys-
tem, with the health care provider telling the patient what
to do and making the final decisions regarding screening
or treatment. More recently, informed decision making
and the related concept of shared decision making are
increasingly being advocated, and several health organiza-
tions recommend that a patient be well informed about the
risks and benefits of screening with PSA, and that he dis-
cusses his screening decision with his health care provider
[5]. Both approaches of IDM and SDM aim to empower
patients to choose among the available options by making
them active participants in the decision making process
[9,10]. In the IDM approach, the patient is presented with
all the information pertinent to making a decision and
then assumes final authority for the decision. In the SDM
approach, the patient is provided with all the relevant
information and works with the health care provider to
reach a decision that reflects the health preference of the
patient [11]. Traditionally, the information relevant to the
clinical decision has been conveyed verbally to the patient
by the health care provider.
An increasingly important part of the IDM and SDM
approaches is decision aids, which are designed to consis-
tently deliver comprehensive and objective information to
the patient. Decision aids, such as an informational video-
tape or pamphlet, have been shown to increase patient
knowledge about prostate cancer and its management
options [12-15]. Information relevant to the clinical deci-
sion conveyed verbally to the patient by the health care
provider can be supplemented with the use of a decision
aid [16]. Several studies have shown that a significantly
lower proportion of patients choose PSA testing among
those who were given decision aids to assist in informed
consent [17,18] and SDM [13,19] compared to those in
control groups. The American Cancer Society, a long-time
advocate of IDM, recommends in its most recent guide-
lines the use of decision aids [8]. Decision aids also have a
potentially important role in malpractice defence by
enabling practitioners to document that the screening
decision of a patient was an informed one based on
reviewing a decision aid [20,21].
Proponents of the IDM and SDM approaches argue
that one of the important benefits of these approaches is
that the final decision for screening or treatment is more
in agreement with the values and best interests of the
patient than in the traditional paternalist approach [8,22].
While this is certainly true, by increasing involvement of
patients in the clinical decision-making process, IDM/
SDM places more of the responsibility and pressure for a
complex decision on the patient.
Challenges to decision-making
In practice, several challenges to decision making for PSA
screening remain. Various prostate cancer screening
guidelines recommend a balanced discussion between
the health care provider and the patient about risks and
benefits of PSA screening prior to screening [7,8]. How-
ever, research suggests that these discussions are not
consistently taking place [16,23], that patients are often
not properly educated about screening [23,24], and that
individuals face biases that may interfere with making an
informed decision [25-27].
Clinicians have been slow to adopt the IDM and SDM
approaches and as a result they are currently underuti-
lized. Practical issues, such as the time required for a
detailed discussion of clinical options with patients, have
limited the adoption of SDM or IDM [16]. Clinicians
under heavy time constraints may find it quicker and
easier to order a PSA test than to carefully counsel the
patient. Fear of malpractice litigation or financial incen-
tives inherent in the health care system have also likely
hindered the adoption of IDM/SDM by clinicians. In a
recent random survey of 375 men aged 40 and older who
had either discussed PSA testing or had a PSA test in the
previous two years, only 55% of men were asked their pre-
ference for screening [23]. In a small random sample of
the medical charts of elderly patients in the VA study [28],
only 4% of ordered PSA tests were reported to be
requested by patients.
Another barrier to decision making is that patients
often lack knowledge of prostate cancer and screening
tools and are not fully informed of the risks and benefits
of screening [24]. A recent survey demonstrates a lack of
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as 48% of respondents failed to answer correctly any one
of three knowledge questions about prostate cancer
screening [23]. Health care providers may not emphasize
in a discussion all the information that patients might
consider important [29], and they may also present infor-
mation in an unbalanced way. In one study, the health
care provider more often emphasized benefits of PSA
screening (71%) than its harms (32%) [23]. Another sur-
vey found that physicians placed less value on providing
information to patients than did patients [30]. Physicians
may also overestimate the level of patient knowledge
about the disease and treatment options [29]. As a result,
patients may not get all the information they need from
their physician to make a decision. SDM and IDM
approaches are only fully effective when patients are truly
well informed [31,32]. The increasing use of decision aids
should help to educate patients about the risks and bene-
fits of screening and also alleviate the time burden on
clinicians and increase the utilization of IDM.
While IDM/SDM approaches are promising for allowing
a patient to make a decision that is concordant with their
values and preferences, barriers to rational thought could
influence the preferences expressed by patients. Tradi-
tional economic decision-making models assume that
individuals are consistent, rational decision-makers. How-
ever, evidence from studies in psychology and behavioural
economics shows that individuals are often not good
judges of what would improve their well-being, and they
frequently make uninformed or suboptimal choices
regarding their own welfare [25-27,33]. Individuals are
subject to an assortment of biases (e.g. discounting, omis-
sion, status quo, loss aversion [25,26,34,35]), and emotion
(e.g., fear, anxiety), which can generate irrational thoughts
that interfere with making informed choices. Status quo
bias will lead a patient to adhere to the path of least resis-
tance even if a superior option exists [34]. Status quo bias
can also be described as a tendency for inertia and going
along with the default option. Omission bias entails the
preference for a more harmful act of omission (not taking
action) over a less harmful act of commission (taking
action) [25]. If a patient’s health care provider always
recommends PSA testing and portrays it as an automatic
course of action, then status quo bias or omission can lead
them to follow this course of action even if it is not in the
patient’s best interest. The idea of discounting future
harms such as incontinence or impotency for the current
benefit of peace of mind from a low PSA value can explain
a decision for an immediate PSA test. A strong emotional
fear of cancer and the desire for an urgent peace of mind
can lead to a rash decision about screening when it is pre-
sented as an immediate option. Patients may also have dif-
ficulty assessing probabilities, and as a result are often
overly optimistic about their own outcome when faced
with the probabilities of survival with treatment options
[36] and overestimate their risk of disease. For example, it
has been reported that some men overestimate their life-
time risk of developing and dying from prostate cancer
[37].
In summary, considering the current challenges to
decision making on PSA screening, there are opportu-
nities to apply new strategies to the existing decision-
making process. Given the widespread promotion of PSA
screening through the media [28,31], by some health-
related organizations and providers, and through social
networks [38], the general enthusiasm for screening in
the United States [39], personal fears and overestimation
of one’s own longevity [40], and the individual and sys-
tem-wide factors influencing health care providers,
patients are more likely to undergo PSA testing than not,
resulting in unnecessary treatment and harms.
Libertarian paternalist strategies for PSA screening
Libertarian paternalism is a philosophy that uses the
insights of behavioural economics to help people better
make better choices [26]. A libertarian paternalistic plan is
aware of the biases that may hinder a rational decision by
individuals and leads to the design of the choice architec-
ture to overcome some of these biases [33]. Major distin-
guishing features of libertarian paternalism that are
relevant for PSA screening decision making include a
default decision rule, the framing of the information influ-
encing the decision, and the timing of the decision. Strate-
gies based on these aspects of LP can be applied to the
IDM/SDM approaches to improve decision making about
PSA screening.
Default decision
In an LP plan or program, there is a default decision rule.
The rule states the default option or decision, which is the
decision automatically made if an individual does not opt
to make a decision of their own. As example, a default
rule could be that every eligible person is automatically
entered into a program (plan A), or conversely, that eligi-
ble persons must elect to enter the program on their own
(plan B). In an LP-based approach, an individual is free to
go against the default setting by making his or her own
decision. If an individual goes against the default when it
is an automatic enrolment (plan A), they opt-out of the
program. Conversely, if the individual decides against the
default when it is an optional enrolment (plan B), they
opt-in to the program. In other words, deciding against a
default option of no required action for participation is
called opt-out, whereas going against inertia to participate
is called opt-in. Therefore, the default decision rule in plan
A corresponds to an opt-out strategy and the rule in plan
B corresponds to an opt-in strategy. Cleary, what is con-
sidered as an opt-in or opt-out strategy depends on the
default option.
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savings plan that has as its default option automatic
enrolment of employees into saving a fixed percent of
their income would require employees to opt out of the
plan if they did not want to save for retirement. A more
common employee retirement savings plan would have a
default of no saving and would require employees to opt
in to the plan to save through the employer. In a libertar-
ian paternalistic plan, the default is carefully selected by
the choice architect with the best interest of the indivi-
dual in mind, and is ideally based on consistent research
evidence. The choice of the default option is important
because individuals must overcome status quo bias in
order to select a non-default option.
T h ec h o i c eo ft h ed e f a u l to p t i o nh a sb e e ns h o w nt ob e
quite influential in both non-clinical and clinical settings.
For example, changing the default option from optional
enrolment (opt-in) to automatic enrolment (opt-out) for
employment-based retirement savings plans has greatly
increased participation rates and likely increased the
long-term financial well-being for many people [41,42].
In another example, people were almost twice as willing
to be organ donors when the default strategy was opt-out
(i.e., people would be considered as organ donors unless
they specifically requested not to be donors) instead of
opt-in [43].
Substantially higher levels of recruitment of patients for
health care research have been seen when the default
strategy is opt-out [44]. Similarly, health survey participa-
tion and response rates are substantially higher when the
default strategy is opt-out compared with opt-in [45,46].
Default policies have also been shown to improve health
care quality. A large body of research has demonstrated
that standing orders for adult immunizations in hospitals
and other settings, for which opting out of receiving
pneumococcal or other vaccines is the default, greatly
increases immunization rates [47]. A default policy to
remove urinary catheters after 72 hours has been recom-
mended to reduce the number of nosocomial infections
[48].
Framing
Framing is another important strategy of libertarian
paternalism that can be influential in decision making.
Framing is the expression of logically equivalent informa-
tion in different ways [49], and can be expressed in either
negative or positive terms. For example, negative framing
would state that a patient has a 20% chance of dying
from a treatment, while positive framing would state the
same patient has an 80% chance of surviving with the
treatment.
An individual may be more likely to select a choice if it
is presented with positive framing [27]. Also when using
framing, emphasizing the potential loss from selecting an
action can be more powerful than emphasizing the
potential gain from that action due to individuals’
tendency to loss aversion [25]. In other words, deciding
o nn o tt a k i n ga na c t i o na n dm i s s i n go u to nab e n e f i t
would be considered more favourable than deciding to
take an action and then be harmed as a result. In prac-
tice, framing has been shown to influence personal
choice when deciding on medical procedures [27,33,50].
In one example, when patients were asked to choose
between two equally efficacious medications, 57% chose
the medication whose benefit was expressed in relative
terms while only 15% chose the medication whose benefit
was expressed in absolute terms [50].
Timing
Timing is another LP strategy that can be used when
designing a choice system to produce better decisions. LP
discourages rash decisions and builds in a sufficient
amount of time before an individual makes a decision,
which can encourage more rational thought and consid-
eration of the available options and how they confirm to
the values of the individual. This time allows for what
Sunstein and Thaler [26] refer to as “sober reflection” of
one’s decision.
In health care settings, including a time delay should
limit the number of decisions based on an immediate,
powerful, and emotional fear of illness or a lack of
understanding of the harmful side-effects of potential
treatment. Timing can also be used to influence action
or inaction through status quo bias, as the duration of
the time delay between presentation of an option and
the opportunity to select it could affect levels of inertia.
A time delay for reflection combined with an opt-in sys-
tem could increase inertia. For example, a substantial
required time delay before deciding on a particularly
risky procedure could decrease the likelihood of select-
ing that option.
Strategies in practice
The LP strategies of a default decision, framing, and
timing can be applied to decision making for PSA
screening in the IDM/SDM approaches. Adding a sys-
tem default decision that minimizes harm may help
reduce overdiagnosis and overtreatment.
The default decision we propose is no PSA screening,
that is, an opt-in system. This default is appropriate for
minimizing harm when benefits are uncertain, which is
the current situation with PSA screening with an absence
of definitive evidence that PSA screening reduces pros-
tate cancer mortality and that the benefits outweigh the
risks. Clearly, this default would be modified should this
situation change based on further research and level of
scientific consensus.
It is noteworthy that the default decision is for both
patients and health care providers using the LP-influenced
approach. This does not mean that clinicians could not
recommend screening, but that the default decision would
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it forces an information transfer to the patient or a discus-
sion with the clinician before a decision to screen occurs.
While the default decision of no PSA screening can be
overridden, its presence would likely reduce the extent of
testing.
This approach requires the use of decision aids and a
consent form for PSA screening to document that a
patient was informed before making a decision. A form
could also be presented for the patient to sign at the time
informational materials are presented to document
receiving the decision aids. These documents could be
important for potential malpractice defence. The decision
aids would be designed to provide an independent and
evidence-based presentation of the positives and nega-
tives of PSA screening, expectantly avoiding patient and
physician bias and overcoming the failure of information
transmission due to clinician time constraints.
Framing could be used in the decision aids and consent
form to emphasize either the benefits of screening (possi-
ble early detection of cancer) or the harms (possible
incontinence and impotence) of screening and the cas-
cade of procedures resulting from a false positive test. A
more negatively framed statement for prostate cancer
screening using PCA and digital rectal examination
would be that out of every 10 abnormal test results, 7
men will not have prostate cancer [14]. The more posi-
tively framed statement of the same results would be that
out of every 10 abnormal test results, 3 men will have
cancer. Emphasizing the potential loss in urinary function
and sexual function over the potential gain of reassurance
of no cancer or early detection of cancer could influence
patient decision making. The nature of the framing used
when presenting information for a choice should depend
on the current state of evidence. With the current situa-
tion of a lack of evidence of the benefits of PSA screen-
ing, the harms should be emphasized more strongly
through framing.
Timing would be used in this approach to PSA screen-
ing decision making to provide the patient time to review
the decision aids and consider the benefits and harms of
screening. After reviewing the informational materials and
carefully considering the options over a reasonable
amount of time, say 1 week, the patient who elects screen-
ing would then be required to sign a written consent form.
This process requires the patient to opt-in to testing only
after a time delay that allows for sober reflection, and
would be similar to the process used to obtain informed
consent from patients for medical procedures. The addi-
tional time for sober reflection afforded by the consent
form and the effort needed to overcome inertia would
likely decrease the number of PSA tests that are requested
based on an immediate, powerful, and emotional fear of
illness or lack of understanding of the harmful side-effects
of potential treatment for prostate cancer.
While a screening approach that adopts libertarian
paternalistic strategies could help reduce overdiagnosis
and overtreatment from PSA screening, there are several
issues to consider for implementation of such an
approach. One issue is who is to take the responsibility for
implementing the approach and making the important
decisions needed for implementation. The default option
must be selected using the current state of scientific evi-
dence. Given a lack of consensus about the screening deci-
sion, the default could be based on the most common
recommendation in the screening guidelines from major
health organizations or, perhaps more justifiably, on the
recommendation from the health organization with the
most rigorous review process for determining a guideline.
The specific set of information to be presented in the deci-
sion aids and consent form must also be decided upon.
For this, a panel of clinical and communication experts
c o u l db ec o n v e n e dt or e v i e wa n dr e c o m m e n dd e c i s i o n
aids.
It could be argued that what we propose raises ethical
concerns because of the default choice of no PSA screen-
ing. In other words, LP imposes certain values and some
individuals might not receive a test from which they might
benefit. Similar arguments have been raised regarding HIV
testing of patients [51], where the default strategy is opt-in
and there are concerns about unforeseen harms for indivi-
duals. We argue, however, that the approach with LP stra-
tegies described is more explicit and honest about
underlying values than the current situation. Our core
values are simply that a cancer screening test should not
be performed without clear and convincing research evi-
dence and consensus that it reduces mortality, and the
fundamental medical principle of first do no harm.
Summary
PSA screening has been over-utilized in the United States
as a preventative measure for prostate cancer, and in
many instances has likely caused more harm than benefit.
Given the current lack of conclusive evidence of the ability
of PSA screening to differentiate between clinically signifi-
cant and indolent localized prostate cancer, and to reduce
prostate cancer mortality, a more structured and conserva-
tive decision-making approach for screening would be
beneficial to minimize harming individuals unnecessarily.
Libertarian paternalism has been used to guide individuals
to making better decisions by designing choice systems
that acknowledge barriers to thoughtful, well-reasoned
decisions. Our proposed application of key libertarian
paternalism strategies to augment the current IDM and
SDM decision-making approaches to PSA screening is
intended to provide patients with the current state of
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rash, uninformed decisions with the potential for signifi-
cant harm while maintaining personal freedom of choice.
We hope definite evidence will emerge and that
improved methods may eventually be able to differenti-
ate between high-grade prostate cancer and clinically
harmless disease, rendering a libertarian paternalistic
approach for PSA screening unnecessary. In the interim
however, while PSA screening remains controversial and
evidence conflicting, this approach to decision-making
can help prevent the overdiagnosis and overtreatment of
prostate cancer.
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